Welcome to our dedicated page for AVALYN PHARMACEUTICALS SEC filings (Ticker: AVLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on AVALYN PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into AVALYN PHARMACEUTICALS's regulatory disclosures and financial reporting.
Avalyn Pharma Inc. director Heather D. Turner received a compensation grant of stock options covering 26,978 shares of common stock. The options have an exercise price of $18.00 per share and expire on April 28, 2036.
According to the vesting terms, 25% of the shares vest and become exercisable on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to her continued service. Following this grant, Turner holds stock options for 26,978 underlying shares directly.
Avalyn Pharma Inc. reported that its Chief Financial Officer, Douglas R. Carlson, received a grant of stock options covering 211,975 shares of Common Stock. These options have an exercise price of $18.0000 per share and expire on April 28, 2036.
According to the vesting schedule, 25% of the shares vest and become exercisable on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments, conditioned on his continued service. Following this award, he holds 211,975 derivative securities linked to Avalyn Pharma stock.
Avalyn Pharma Inc. director Kate Haviland received a new stock option grant covering 26,978 shares of common stock. The option has an exercise price of $18.00 per share and expires on April 28, 2036.
This award is compensation-related, not an open-market trade. According to the vesting terms, 25% of the shares underlying the option vest on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to her continued service. Following this grant, she holds 26,978 stock options directly from this award.
Wellington Biomedical Innovation Master Investors (Cayman) II L.P., a 10% owner of Avalyn Pharma Inc., reported converting its preferred stock into common shares. On May 1, 2026, it acquired 1,275,486 shares of Common Stock through the automatic conversion of Series C-1 and Series D Convertible Preferred Stock immediately prior to Avalyn’s initial public offering. Following these transactions, the reporting holder’s remaining position consists of common stock, with the preferred stock fully converted.
Avalyn Pharma director Erin Lavelle received a grant of stock options covering 26,978 shares of common stock at an exercise price of $18.00 per share. Twenty-five percent vest on September 12, 2025, with the remaining 75% vesting in 36 equal monthly installments, subject to continued service.
Avalyn Pharma Inc. reported corporate governance changes tied to its initial public offering. Immediately before the IPO, the company filed an amended and restated certificate of incorporation in Delaware, fully replacing its prior charter.
The new charter authorizes 700,000,000 shares of common stock, split into 500,000,000 voting common shares and 200,000,000 non-voting common shares, and authorizes 10,000,000 shares of undesignated preferred stock that the board may issue in one or more series. It also removes references to the company’s previous preferred stock series.
At the same time, Avalyn’s amended and restated bylaws became effective. These bylaws overhaul procedures for stockholder meetings, introduce advance notice requirements for stockholder proposals and director nominations, and align the bylaws with the updated charter provisions.
Novo Holdings A/S, a more than ten percent owner of Avalyn Pharma Inc., has filed an initial ownership report showing its preferred stock positions in the company. The filing lists holdings of Series A, B, C-1, C-2 and D Preferred Stock, each convertible into voting common stock.
Each preferred share is convertible into voting common stock on a 1-for-19.2417 basis at the holder’s election and will convert automatically upon the closing of Avalyn Pharma’s initial public offering, with no expiration date. These entries disclose existing ownership rather than new purchases or sales.
Avalyn Pharma Inc. director Erin Lavelle filed an initial ownership report showing a stock option to buy 43,928 shares of common stock at an exercise price of $4.62 per share. The option expires on July 23, 2034, and one-eighth of the underlying shares vest in substantially equal quarterly installments starting from July 24, 2024, contingent on continued service.
Avalyn Pharma Inc. Chief Operating Officer Melissa Rhodes filed an initial ownership report showing her existing stock option holdings in the company. She holds stock options over 111,123 shares of common stock with a $4.81 exercise price expiring on September 10, 2035, and options over 183,938 shares with a $4.62 exercise price expiring on January 25, 2034.
For the first option, 25% of the underlying shares vested and became exercisable on September 11, 2024, with the remaining 75% vesting in thirty-six substantially equal monthly installments, subject to her continued service. For the second, 25% of the shares vest on May 29, 2026, with the remaining 75% vesting in thirty-six substantially equal monthly installments on the same service-based terms.
Avalyn Pharma Inc. director Heather D. Turner reported her initial equity holdings. The filing shows a stock option giving her the right to buy 64,919 shares of common stock at an exercise price of $5.58 per share, expiring on October 29, 2034.
According to the vesting terms, 1/8 of the shares underlying this option vest in substantially equal quarterly installments on each quarterly anniversary of October 30, 2024, as long as she continues in service. This is a compensation-related option holding, not a buy or sell transaction.